Completed PHASE3 INTERVENTIONAL 1-arm NCT00126412

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma

Sponsor: GE Healthcare

Conditions Neuroblastoma Pheochromocytoma

Interventions 123I-mIBG (meta-iodobenzylguanidine)

Updated 6 times since 2017 Last updated: May 29, 2019 Started: Aug 2, 2005 Primary completion: Sep 27, 2006 Completion: Sep 27, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Neuroblastoma and Pheochromocytoma, this trial is completed. The trial is conducted by GE Healthcare and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Jun 2019 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GE Healthcare

Data source: GE Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Princeton, United States